Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
about
(1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism.Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Metabolic imaging in obesity: underlying mechanisms and consequences in the whole body.Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure.Waist circumference adjusted for body mass index and intra-abdominal fat mass.Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus.Fatty heart, cardiac damage, and inflammation.Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.Seeing is believing: dietary fatty acids hurry up from the stomach to the heart of patients with impaired glucose tolerance.Recent advances in metabolic imaging.Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion.Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double
P2860
Q30560950-F2F64CF9-25E8-416D-8BC6-9DCF59866B55Q30583012-5037342E-B45B-4BEE-8386-67A9A88363A9Q30991322-950667EB-5186-41A7-9757-2018A09A8619Q33603593-47B790C0-1B3E-460C-A7BE-B707C377F756Q33817323-6739EFB1-74E3-4BCE-802E-3FA48C887EAEQ34182363-11E57CEA-316E-4A4B-84BB-ED81AB88AA7EQ34506453-5E9D8C36-BD64-4479-8857-7B22E325D431Q35760308-5871E349-E951-4849-A331-6905B662F324Q36259181-5202AEE7-DD36-4E2E-B278-4FF71483644AQ36339509-A94F3BDD-FBD1-422C-A956-8CD6786ED1FFQ38156683-D4895F28-D73E-46F2-8C4E-75AC9D10F0F4Q38920729-4D46ABC5-3DFD-49DE-AF4A-290212E03FCFQ46675779-BA7CC879-52A9-4C53-8F09-D95CC475EC15Q53631221-80BB225A-ED3D-4F0C-98D6-D8A45A3B53B8
P2860
Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@en
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@nl
type
label
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@en
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@nl
prefLabel
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@en
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@nl
P2093
P2860
P50
P1476
Trimetazidine reduces endogeno ...... al efficiency in obese humans.
@en
P2093
Helena Tuunanen
Jussi P Pärkkä
Kjell Någren
Markku Taittonen
Pirjo Nuutila
Riitta Parkkola
Romina Maggio
Sara Rigazio
Tapio Viljanen
Uberto Pagotto
P2860
P304
P356
10.1111/J.1755-5922.2011.00275.X
P577
2011-07-31T00:00:00Z